-

Hims & Hers Acquires US-based Peptide Facility

The acquisition will strengthen the long-term durability of the company’s domestic supply chain, helping to ensure Americans can consistently access personalized medications

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc., the leading health and wellness platform, today announced an acquisition that will further verticalize the company’s long-term ability to deliver personalized medications. The company has acquired a US-based peptide facility based in California. The acquisition will enable the company to strengthen the long-term durability of its domestic supply chain to meet the growing demand from Americans for personalized healthcare and treatment options.

“The future of healthcare must be centered on the customer, which is why our operational structure is built to scale personalized care to more individuals at the highest standard of quality and safety, and with a focus on long-term consistency and availability,” said Melissa Baird, COO of Hims & Hers. “We're building our supply chain to enable more Americans to access care, including personalized treatments designed around their needs. This acquisition is a reflection of our commitment to those goals and our ongoing investment in the customer from start to finish.”

Following the company’s past acquisitions of 503A and 503B facilities, this additional facility deepens the company’s commitment to maintaining operations in the United States for better insight into cost, availability and quality, more fully verticalizing the efficiency and durability of the supply chain, and furthering the company’s focus on quality and safety for every customer on the platform. In addition, the peptide capabilities made possible through this acquisition position the company in the coming years to explore exciting advances in peptide innovation, including across areas of consumer need such as preventive health, metabolic optimization, cognitive performance, recovery science, and biological resistances.

The acquisition closed in early February, and Hims & Hers expects to continue strengthening infrastructure capabilities as demand for personalized treatment continues to grow.

For more information, visit www.hims.com/american-made.

About Hims & Hers Health, Inc

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.

Contacts

Press Contact
Abby Reisinger
press@forhims.com

Hims & Hers

NYSE:HIMS

Release Versions

Contacts

Press Contact
Abby Reisinger
press@forhims.com

More News From Hims & Hers

Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2025 in a shareholder letter that is posted at investors.hims.com. “More than 2.5 million subscribers now rely on us for a healthcare experience that is both accessible and deeply personal – and we believe we’re well on our way to becoming the global leade...

Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced it has entered into a definitive agreement to acquire Eucalyptus, an international leader in digital health, accelerating the company’s ability to bring access to high-quality, personalized care to more people across the world. As its US business continues to grow, Hims & Hers will be well-positioned, upon closing of the acquisition, to expand into Australia a...

Hims & Hers Expands Personalized Weight Loss Portfolio with Access to Compounded Semaglutide Pills Starting at $49/Month*

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced an expansion of its weight loss specialty by enabling providers to prescribe a Compounded Semaglutide Pill with the same active ingredient as Wegovy®**. This needle-free treatment joins a full suite of weight loss solutions designed to meet the specific needs and preferences of individual customers. By leveraging nearly a decade of infrastructur...
Back to Newsroom